“Digital Pathology Market Worth $631.43 Million in 2019 “, says Visiongain report

19 December 2019
Pharma

Visiongain’s new report the Digital Pathology Market Report 2019-2029: Forecasts by Product (Scanner, Software, Communication System), Type (Human, Veterinary), Application (Teleconsultation, Disease Diagnosis, Drug Discovery), End User (Pharmaceutical & Biotechnology Companies), plus analysis of leading companies indicates that the global Digital Pathology market will attain $1,796.4 million revenue by 2029.

Global Digital Pathology market is expected to grow on account of increasing usage in drug development and companion diagnostics. The market is expected to grow at a healthy CAGR of 11.02% over the projected period. In addition, an increase in cancer incidence, an increase in the workload of pathologists, and an ever-increasing number of clinical and pre-clinical studies are other significant considerations attributable to the development of the digital pathology industry, and comparable trends are anticipated to reinforce the market concentration of Digital Pathology over the projected period.

Furthermore, the growing geriatric population prone to chronic circumstances is also anticipated to increase demand for sophisticated diagnostic methods. Chronic illnesses can be ascribed to elevated mortality rates, according to a research released in Medscape. It becomes essential to opt for sophisticated diagnostic and imaging options due to the elevated incidence of cardiovascular diseases.

In 2019, North America Digital Pathology market accounted for more than 30% of overall market share. Continuous deployment of R&D investments, supporting public projects related to the development of sophisticated systems, increasing digital imaging acceptance, and the existence of significant players are important contributing factors expected to boost market penetration of Digital Pathology over the forecast period.

The Asia Pacific is anticipated to grow with the fastest growth rate owing to growing penetration of digital imaging in developing economies like India, Japan and China, investments in the medical & healthcare technology field, and the presence of untapped opportunities will offer lucrative growth for digital pathology market in coming years.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

 

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever